Read articles on the main presentations of the third day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Daniel Weilenmann, entitled “Is the PCI risk higher in patients with severe Aortic Stenosis? How can we reduce the risk?“. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
Courtesy of Dr. Carlos Fava. Aortic stenosis can present different hemodynamic patterns, such as low flow and low gradient with reduced or preserved ventricular function. However, evidence on the evolution of different hemodynamic patterns after transcatheter aortic valve replacement (TAVR) is limited. This study consisted in a retrospective analysis of 368 patients who underwent TAVR. The population was divided in<a href="https://solaci.org/en/2017/07/26/how-can-we-classify-aortic-stenosis-in-patients-who-underwent-tavr/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. It is known that patients with low gradient aortic stenosis show poor evolution with medical treatment and, in addition, present high mortality rate with surgery. As regards TAVR, a far simpler procedure compared to surgery, there is contradicting evidence; while some studies claim it holds comparable risks, others have found<a href="https://solaci.org/en/2017/06/01/low-gradient-aortic-stenosis-wont-improve-with-tavr/" title="Read more" >...</a>
Ventricular dysfunction and moderate aortic stenosis are more frequent with advancing age and often coexist. Afterload reduction is one of the main pillars of pharmacological treatment of heart failure, and aortic stenosis (even that of moderate severity) increases the afterload. Nowadays, aortic valve replacement is only formally indicated for symptomatic severe aortic stenosis. This<a href="https://solaci.org/en/2017/05/25/moderate-aortic-stenosis-and-ventricular-dysfunction-should-valve-replacement-come-sooner/" title="Read more" >...</a>
This work studies the natural history of aortic stenosis and the optimal timing to intervene elderly patients with asymptomatic severe aortic stenosis. This disease is increasingly misdiagnosed in the elderly population, and this goes hand in hand with enhanced therapeutic options. Prior studies on the natural history of this disease were made on<a href="https://solaci.org/en/2017/02/14/asymptomatic-severe-aortic-stenosis-in-the-elderly-when-to-intervene/" title="Read more" >...</a>
Patients with low-flow, low-gradient severe symptomatic aortic stenosis associated with severe impairment of the left ventricular systolic function have shown acceptable outcomes after transcatheter aortic valve replacement (TAVR), according to the multicenter TOPAS-TAVI registry, which demonstrated a relatively low 30-day mortality rate. Considering the very high risk presented by this population involved, a 30-day<a href="https://solaci.org/en/2017/01/06/tavr-in-low-flow-low-gradient-aortic-stenosis-and-severe-impairment-of-systolic-function/" title="Read more" >...</a>
Original Title: Natural history, diagnostic approaches, and therapeutic strategies for patients with asymptomatic severe aortic stenosis. Reference: Généreux P et al. J Am Coll Cardiol. 2016; Epub ahead of print. Given that transcatheter aortic valve replacement (TAVI) is now being prescribed to lower risk patients, some wonder whether it is time to study the benefit<a href="https://solaci.org/en/2016/04/24/tavi-in-asymptomatic-severe-aortic-stenosis/" title="Read more" >...</a>
Left Main Disease angioplasty in patients with severe aortic stenosis Javier Ibáñez, MD
Augusto Pichard2014-08-08 Director Innovation and Structural Heart Disease, Vice Chair, Medstar Heart Institute, Medstar Washington Hospital Center. Professor of Medicine (Cardiology),Georgetown University Medical School.Washington, DC
